Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2239-2243

  Inciarte Mundo, José ^a   Ruiz Esquide, Virginia ^a   Hernández, Maria Victoria ^a   Cañete, Juan D ^a   Cabrera Villalba, Sonia Raquel ^a   Ramirez, Julio ^a   Yagüe, Jordi ^a   Sanmarti, Raimon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Calprotectin; Disease activity; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DAS28; DISEASE ACTIVITY; DRUG BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX;

EID: 84983189195     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev251     Document Type: Article

References (20)

1. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin- 6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
2. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL- 6 inhibitor-evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007;6:1162-7.
3. Nishimoto N, Miyasaka N, Yamamoto K et al. Long-term safety and efficacy of tocilizumab, an anti-IL- 6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4.
4. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4 (Suppl 3):P233-42.
5. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44.
6. Smolen J, Aletaha D. Interleukin- 6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011;63:43-52.
7. Donato R, Cannon BR, Geczy CL et al. Functions of S100 proteins. Curr Mol Med 2013;13:24-57.
8. Kerkhoff C, Eue I, Sorg C. The regulatory role of MRP8 (S100A8) and MRP 14 (S100A9) in the transendothelial migration of human leukocytes. Pathobiology 1999;67:230-2.
9. Berntzen HB, Ölmez Ü, Fagerhol MK et al. The leukocyte protein L 1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991,20:74-82.
10. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L 1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416-20.
11. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum (2008);58:2968-80.
12. Kawashiri SY, Kawakami A, Iwamoto N et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol 2011;21:365-9.
13. Hammer HB, Odegard S, Fagerhol MK et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1093-7.
14. Sang-Youn J, Young-Beon P, You-Jung H et al. Serum calprotectin as marker for disease activity and severity in adult-onset Still's disease. J Rheumatol 2010;37:5.
15. Moncrieffe H, Ursu S, Holzinger D et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/ 14 protein. Rheumatology 2013;52:1467-76.
16. Hansson C, Eriksson C, Alenius G-M. S-Calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res 2014;2014:696415.
17. Hammer HB, Fagerho MK, Wien TN et al. The soluble biomarker calprotectin (a S 100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther 2011;13:R178.
18. Hammer HB, Ødegård S, Syversen SW et al. Calprotectin (a major S 100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:150-4.
19. Pharmaceuticals and Medical Devices Agency Report of Deliberation Results for Actemra 2008. http://www.pmda. go.jp/english/service/pdf/actemra.pdf ( 25 August 2014, date last accessed).
20. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30:1426-35.